ATREVIA® 360° Arrives in the Bolivian Veterinary Market with True 360 ​​Protection

On October 8, 2026, the city of Santa Cruz de la Sierra, Bolivia, hosted the launch of a new antiparasitic that is revolutionizing the pet market: Atrevia® 360°. This oral ecto- and endoparasiticide sets a new standard for comprehensive dog protection.

Petmedica®—Agrovet Market®’s specialized companion animal division—presented this latest innovation to the veterinary community alongside its strategic partner in Bolivia, Univet, thereby consolidating its leadership in the region. The event generated significant interest within the sector, drawing approximately 300 professionals, including veterinarians, clinic owners, and animal health specialists.

Veterinarian Luis Alfredo Chávez, the company’s Technical-Commercial Manager, presented field studies demonstrating the product's high standards of safety and efficacy. He also detailed the key attributes and value proposition of Atrevia® 360°—which features a patent currently pending registration (PCT WO/2024/177520)—highlighting its unique combination of three active ingredients: fluralaner, moxidectin, and praziquantel. This synergy provides prolonged action (up to three months) against ectoparasites such as fleas, ticks, and mites, complemented by broad-spectrum activity against endoparasites, including cestodes and nematodes. Furthermore, the product ensures stress-free therapeutic compliance thanks to SmartCap® technology, which masks bitter flavors and guarantees superior palatability, facilitating voluntary administration.

Petmedica® thanks the Bolivian veterinary community for the excellent reception and reaffirms its commitment to developing and delivering innovative veterinary solutions that improve pets' quality of life.

Learn more about the complete Atrevia line at www.atrevia.vet.